Cargando…

A Modular Microarray Imaging System for Highly Specific COVID-19 Antibody Testing

To detect the presence of antibodies in blood against SARS-CoV-2 in a highly sensitive and specific manner, here we describe a robust, inexpensive ($200), 3D-printable portable imaging platform (TinyArray imager) that can be deployed immediately in areas with minimal infrastructure to read coronavir...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedde, Per Niklas, Abram, Timothy J., Jain, Aarti, Nakajima, Rie, de Assis, Rafael Ramiro, Pearce, Trevor, Jasinskas, Algis, Toosky, Melody N., Khan, Saahir, Felgner, Philip L., Gratton, Enrico, Zhao, Weian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263497/
https://www.ncbi.nlm.nih.gov/pubmed/32511369
http://dx.doi.org/10.1101/2020.05.22.111518
Descripción
Sumario:To detect the presence of antibodies in blood against SARS-CoV-2 in a highly sensitive and specific manner, here we describe a robust, inexpensive ($200), 3D-printable portable imaging platform (TinyArray imager) that can be deployed immediately in areas with minimal infrastructure to read coronavirus antigen microarrays (CoVAMs) that contain a panel of antigens from SARS-CoV-2, SARS-1, MERS, and other respiratory viruses. Application includes basic laboratories and makeshift field clinics where a few drops of blood from a finger prick could be rapidly tested in parallel for the presence of antibodies to SARS-CoV-2 with a test turnaround time of only 2–4 h. To evaluate our imaging device, we probed and imaged coronavirus microarrays with COVID-19-positive and negative sera and achieved a performance on par with a commercial microarray reader 100x more expensive than our imaging device. This work will enable large scale serosurveillance, which can play an important role in the months and years to come to implement efficient containment and mitigation measures, as well as help develop therapeutics and vaccines to treat and prevent the spread of COVID-19.